Sagimet Biosciences (SGMT) News Today $4.95 -0.12 (-2.37%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Sagimet Biosciences (NASDAQ:SGMT) Stock, Insider Trading ActivityDecember 18 at 12:09 AM | benzinga.comSagimet Biosciences Inc. (NASDAQ:SGMT) Receives $23.00 Average Price Target from BrokeragesDecember 12, 2024 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Chromadex (CDXC) and Sagimet Biosciences, Inc. Class A (SGMT)December 8, 2024 | markets.businessinsider.comOppenheimer Initiates Coverage of Sagimet Biosciences (SGMT) with Outperform RecommendationDecember 7, 2024 | msn.comSagimet started at outperform by Oppenheimer, MASH drug citedDecember 7, 2024 | seekingalpha.comSagimet Biosciences (NASDAQ:SGMT) Now Covered by Analysts at OppenheimerOppenheimer began coverage on Sagimet Biosciences in a report on Friday. They set an "outperform" rating and a $30.00 target price on the stock.December 6, 2024 | marketbeat.comSagimet Biosciences price target lowered to $31 from $32 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.comSagimet Biosciences initiated with an Outperform at OppenheimerDecember 5, 2024 | markets.businessinsider.comSagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | finance.yahoo.comSagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | finance.yahoo.comSagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from TD CowenNovember 22, 2024 | markets.businessinsider.comSagimet Biosciences participates ik,on NoNovember 20, 2024 | markets.businessinsider.comSagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024November 18, 2024 | markets.businessinsider.comSagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor daNovember 18, 2024 | markets.businessinsider.comPromising Outlook for Sagimet Biosciences: Buy Rating Driven by Denifanstat’s Clinical Success and Phase 3 MASH Program InitiationNovember 16, 2024 | markets.businessinsider.comSagimet Biosciences (NASDAQ:SGMT) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $32.00 target price on shares of Sagimet Biosciences in a research report on Friday.November 15, 2024 | marketbeat.comSagimet Biosciences, Inc.: Strategic Advancements and Financial Robustness Drive Buy RatingNovember 15, 2024 | markets.businessinsider.comSagimet Biosciences reports Q3 EPS (45c) vs (35c) last yearNovember 14, 2024 | markets.businessinsider.comSagimet: More Than Just A MASH Drug Development BiotechNovember 14, 2024 | seekingalpha.comSagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 14, 2024 | finance.yahoo.comSagimet draws buy at UBS on MASH opportunityNovember 13, 2024 | seekingalpha.comUBS Initiates Coverage of Sagimet Biosciences (SGMT) with Buy RecommendationNovember 13, 2024 | msn.comSagimet Biosciences: Promising Drug Denifanstat and Market Potential Drive Buy RatingNovember 12, 2024 | markets.businessinsider.comSagimet Biosciences initiated with a Buy at UBSNovember 12, 2024 | markets.businessinsider.comSagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assignedNovember 12, 2024 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Coverage Initiated by Analysts at UBS GroupUBS Group started coverage on Sagimet Biosciences in a research note on Tuesday. They issued a "buy" rating and a $12.00 price target on the stock.November 12, 2024 | marketbeat.comAscletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of AcneNovember 12, 2024 | prnewswire.comSagimet Biosciences to Participate in the UBS Global Healthcare ConferenceNovember 8, 2024 | markets.businessinsider.comSagimet’s denifanstat enters Phase III trials for MASH treatmentNovember 1, 2024 | msn.comSagimet Biosciences, Inc. Class A (SGMT) Receives a Rating Update from a Top AnalystOctober 31, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Sagimet Biosciences, Inc. Class A (SGMT), Boston Scientific (BSX)October 31, 2024 | markets.businessinsider.comSagimet Biosciences (NASDAQ:SGMT) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $32.00 target price on shares of Sagimet Biosciences in a research note on Thursday.October 31, 2024 | marketbeat.comSagimet Biosciences completes End-of-Phase 2 meeting with FDA on denifanstatOctober 30, 2024 | markets.businessinsider.comShort Interest in Sagimet Biosciences Inc. (NASDAQ:SGMT) Grows By 102.0%Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) was the recipient of a large growth in short interest in October. As of October 15th, there was short interest totalling 3,980,000 shares, a growth of 102.0% from the September 30th total of 1,970,000 shares. Approximately 18.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,310,000 shares, the days-to-cover ratio is presently 3.0 days.October 26, 2024 | marketbeat.comSagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate DenifanstatOctober 19, 2024 | seekingalpha.comSagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024October 16, 2024 | finance.yahoo.comSagimet Gains on Latest NumbersOctober 11, 2024 | baystreet.caSagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & HepatologyOctober 11, 2024 | globenewswire.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Renaissance Technologies LLCRenaissance Technologies LLC reduced its holdings in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 42.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 242,400 shares of the company's stoOctober 8, 2024 | marketbeat.comSagimet Biosciences’ Denifanstat Receives Buy Rating on FDA’s BTD and Promising Trial ResultsOctober 4, 2024 | markets.businessinsider.comLeerink maintains Sagimet Biosciences shares at Outperform ratingOctober 3, 2024 | uk.investing.com3 Penny Stocks to Watch Now, 10/3/24October 3, 2024 | msn.comSagimet Biosciences (NASDAQ:SGMT) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comBuy Rating for Sagimet Biosciences on Strong Phase 2b Results and Favorable Valuation ModelOctober 2, 2024 | markets.businessinsider.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Point72 Asset Management L.P.Point72 Asset Management L.P. decreased its holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 11.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,366,090 shares of the company's stoOctober 2, 2024 | marketbeat.comBuy Rating Justified: Sagimet Biosciences’ Denifanstat Poised to Transform NASH Treatment LandscapeOctober 1, 2024 | markets.businessinsider.comSagimet Shares Rise Premarket on FDA Breakthrough DesignationOctober 1, 2024 | marketwatch.comSagimet Biosciences Gets FDA Breakthrough Therapy Designation For DenifanstatOctober 1, 2024 | markets.businessinsider.comSagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASHOctober 1, 2024 | globenewswire.comSagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2024 | globenewswire.com Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin SGMT Media Mentions By Week SGMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMT News Sentiment▼0.000.60▲Average Medical News Sentiment SGMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMT Articles This Week▼12▲SGMT Articles Average Week Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Prothena News Today Entrada Therapeutics News Today Arbutus Biopharma News Today Tectonic Therapeutic News Today CARGO Therapeutics News Today Stoke Therapeutics News Today Altimmune News Today Exscientia News Today Terns Pharmaceuticals News Today ORIC Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
